![Matej Mikulic](https://cdn.statcdn.com/static/../CMS/contactperson/ERI285_1713877581.png)
Enterprise value of top companies in non-oncology rare disease therapeutics 2017
This statistic shows the enterprise value of leading pure players in non-oncology rare disease therapeutics worldwide as of 2017. In 2017, the value of Biogen which manufactures especially multiple sclerosis therapeutics stood at nearly 70 billion U.S. dollars.